公开(公告)号：US06673629B2

公开(公告)日：2004-01-06

申请号：US09007651

申请日：1998-01-15

Applicant: Toru Yoshimura ,  Toshihiro Ogasawara ,  Michihiro Saito ,  John P. Groff

Inventor： Toru Yoshimura ,  Toshihiro Ogasawara ,  Michihiro Saito ,  John P. Groff

IPC: G01N33533

CPC classification number: G01N33/56988 ,  G01N30/90 ,  G01N33/558 ,  G01N33/5695 ,  G01N33/571 ,  G01N33/5764 ,  G01N2333/162 ,  G01N2333/20 ,  G01N2333/35 ,  Y10S435/962 ,  Y10S436/824 ,  Y10S436/825 ,  Y10T436/105831 ,  Y10T436/106664

Abstract: A chromatography assay device and method for use with whole blood samples utilizing a red blood cell separating agent to aggregate red blood cells and permit plasma or serum to flow by capillary action and a neutralizing agent to neutralize any effects the red blood cell separating agent may have on the device and method.

Abstract translation: 一种色谱分析装置和方法，用于利用红细胞分离剂聚集红细胞并允许血浆或血清通过毛细作用流动的全血样品和中和剂以中和红细胞分离剂可能具有的任何作用 在设备和方法上。

公开(公告)号：US06605427B2

公开(公告)日：2003-08-12

申请号：US09779451

申请日：2001-02-09

Applicant: Carl T. Wild ,  Graham P. Allaway

Inventor： Carl T. Wild ,  Graham P. Allaway

IPC: C12Q170

CPC classification number: G01N33/5047 ,  G01N33/5008 ,  G01N33/5091 ,  G01N33/56983 ,  G01N33/56988 ,  G01N2333/162 ,  Y10S977/927 ,  Y10S977/959

Abstract: The invention is directed to a methods for identifying compounds that inhibit or prevent infection of cells by enveloped viruses such as HIV-1 by preventing or disrupting conformational changes in the viral transmembrane protein that are required for virus fusion with those cells, and the compounds discovered by such methods. The invention also includes using these assays as diagnostic assays to detect antibodies in virus infected individuals that inhibit the viral entry processes.

公开(公告)号：US20030004323A1

公开(公告)日：2003-01-02

申请号：US08911824

申请日：1997-08-15

Inventor： JOHN R. HACKETT, JR. ,  JULIE YAMAGUCHI ,  ALAN M. GOLDEN ,  CATHERINE A. BRENNAN ,  ROBERT K. HICKMAN ,  SUSHIL G. DEVARE

IPC: C07H021/02 ,  C07H021/04 ,  C12Q001/70

CPC classification number: C07K14/005 ,  A61K39/00 ,  C07K2319/00 ,  C12N2740/16122 ,  G01N2333/162

Abstract: Isolated HIV-1 Group O env polypeptides obtained from the HIV-1 isolate HAM112 are claimed, as well as (a) antigen constructs comprising fusions of one or more of each of HIV-1 Group O env polypeptides and HIV-1 Group M env polypeptide and (b) further antigen constructs containing additional Group O sequences and especially the gp4l IDR of isolate HAM112. Also claimed are polynucleotide sequences encoding the above, expression vectors comprising the same, host cells transformed thereby, and immunoassay methods and kits utilizing the antigen constructs of the invention.

Abstract translation: 要求保护从HIV-1分离株HAM112获得的分离的HIV-1组O env多肽，以及（a）包含HIV-1组O型多肽和HIV-1组M env中的一种或多种的融合物的抗原构建体 多肽和（b）含有另外的组O序列，特别是分离的HAM112的gp4I IDR的其它抗原构建体。 还要求保护的是编码上述的多核苷酸序列，包含其的表达载体，由此转化的宿主细胞，以及利用本发明的抗原构建体的免疫测定方法和试剂盒。

公开(公告)号：US20020051967A1

公开(公告)日：2002-05-02

申请号：US09862511

申请日：2001-05-23

Applicant: Institut Pasteur

Inventor： Luc Montagnier ,  Solange Chamaret ,  Denise Guetard ,  Marc Alizon ,  Francois Clavel ,  Mireille Guyader ,  Pierre Sonigo ,  Francoise Brun-Vezinet ,  Marianne Rey ,  Christine Rouzioux ,  Christine Katlama

IPC: C12Q001/70 ,  C12N007/00 ,  C07H021/02

CPC classification number: C07K7/06 ,  A61K38/00 ,  A61K39/00 ,  C07K14/005 ,  C12N7/00 ,  C12N2740/16021 ,  C12N2740/16122 ,  C12N2740/16222 ,  C12Q1/703 ,  G01N33/56988 ,  G01N2333/162 ,  G01N2469/20

Abstract: The invention relates to a new class of retroviruses, designated by HIV-2, of which samples have been deposited to the ECACC under numbers 87.01.1001 and 87.01.1002 and to the NCIB under numbers 12.398 and 12.399. It relates also to antigens capable to be obtained from this virus, particularly proteins p12, p16, p26 and gp14O. These various antigens can be used for the diagnosis of the disease, especially by contacting these antigens with a serum of a patient submitted to the diagnosis. It relates to immunogenic compositions containing more particularly the glycoprotein gp14O. Finally it concerns nucleotidic sequences, which can be used especially as hybridization probes, derived from the RNA of HIV-2.

Abstract translation: 本发明涉及由HIV-2指定的一类新的逆转录病毒，其中样品已经按照号码87.01.1001和87.01.1002保藏在ECACC，编号12.398和12.399的NCIB。 它还涉及能够从该病毒获得的抗原，特别是蛋白质p12，p16，p26和gp14O。 这些各种抗原可以用于疾病的诊断，特别是通过将这些抗原与患者的血清接触进行诊断。 本发明涉及更具体地包含糖蛋白gp14O的免疫原性组合物。 最后，它涉及核苷酸序列，其可以特别用作衍生自HIV-2的RNA的杂交探针。

公开(公告)号：US06322964B1

公开(公告)日：2001-11-27

申请号：US08268388

申请日：1994-06-30

Applicant: Wesley L. Cosand ,  Andrew J. Watson ,  Raymond L. Houghton ,  Luc Montagnier ,  Marc Alizon ,  Solange Chamaret

Inventor： Wesley L. Cosand ,  Andrew J. Watson ,  Raymond L. Houghton ,  Luc Montagnier ,  Marc Alizon ,  Solange Chamaret

IPC: C12Q170

CPC classification number: C07K7/06 ,  A61K38/00 ,  A61K39/00 ,  C07K14/005 ,  C12N7/00 ,  C12N2740/16122 ,  C12N2740/16222 ,  C12Q1/703 ,  G01N33/56988 ,  G01N2333/162 ,  G01N2469/20

Abstract: Peptide sequences are disclosed which immunologically mimic proteins encoded by the env and gag regions of LAV-2, a retrovirus associated with AIDS. The peptide can be used in various specific binding assays to detect the presence of antibodies to LAV-2 in individuals previously exposed to the virus. The peptides enable one to distinguish the presence of antibodies to LAV-2 from antibodies to HIV-1.

Abstract translation: 公开了肽序列，其免疫模拟由与HIV相关的逆转录病毒的LAV-2的env和gag区编码的蛋白质。 该肽可用于各种特异性结合测定以检测先前暴露于病毒的个体中LAV-2的抗体的存在。 这些肽使得人们能够将抗体与LAV-2的区别从抗体与HIV-1区分开来。

公开(公告)号：US20010039007A1

公开(公告)日：2001-11-08

申请号：US09296534

申请日：1999-04-22

Inventor： ROBERT HALLOWITZ ,  VIRGINIA SALAS

IPC: C12Q001/00 ,  C12Q001/70

CPC classification number: G01N33/56972 ,  G01N33/56988 ,  G01N2333/162

Abstract: The present invention relates to a new HIV status of a patient called nulllatent viral load.null To measure the nulllatent viral load,null in accordance with a preferred embodiment of the present invention, a population of sample cells is obtained from a desired source, such as an infected patient. The sample cell population is depleted of overtly infected cells and cells harboring active virus, to produce a subset of nullresting cellsnull comprising uninfected and latently-infected cells. This subset is treated with an agent and/or condition that activates the latent virus in the host cell genome and results in a productive infection. The thus-produced infection reflects the nulllatent viral loadnull of the host because it reveals the presence of quiescent virus in cells. The latent viral load is useful in assessing a patient's disease status and the efficacy of highly active antiretroviral therapy and other treatment protocols.

Abstract translation: 本发明涉及称为“潜伏病毒载量”的患者的新HIV状态。 为了测量根据本发明的优选实施方案的“潜伏病毒载量”，从所需来源（例如被感染的患者）获得一组样品细胞。 样本细胞群体被消耗了明显感染的细胞和携带活性病毒的细胞，以产生包含未感染和潜伏感染细胞的“静息细胞”的子集。 使用激活宿主细胞基因组中的潜伏病毒并导致生产性感染的试剂和/或病症来治疗该亚型。 由此产生的感染反映了宿主的“潜伏病毒载量”，因为它揭示了细胞中静止病毒的存在。 潜伏病毒载量可用于评估患者的疾病状况和高度活跃的抗逆转录病毒疗法及其他治疗方案的疗效。

公开(公告)号：US06261762B1

公开(公告)日：2001-07-17

申请号：US08774736

申请日：1997-01-02

Applicant: Marc Alizon ,  Luc Montagnier ,  Denise Duetard ,  Francois Clavel ,  Pierre Sonigo ,  Mireille Guyader

Inventor： Marc Alizon ,  Luc Montagnier ,  Denise Duetard ,  Francois Clavel ,  Pierre Sonigo ,  Mireille Guyader

IPC: C12Q170

CPC classification number: C07K7/06 ,  A61K38/00 ,  A61K39/00 ,  C07K14/005 ,  C12N7/00 ,  C12N2740/15022 ,  C12N2740/16021 ,  C12N2740/16122 ,  C12N2740/16222 ,  C12N2740/16322 ,  C12Q1/703 ,  G01N33/56988 ,  G01N2333/162 ,  G01N2469/20 ,  Y10S435/974 ,  Y10S435/975 ,  Y10S530/81

Abstract: A method for diagnosing an HIV-2 (LAV-II) infection and a kit containing reagents for the same is disclosed. These reagents include cDNA probes which are capable of hybridizing to at least a portion of the genome of HIV-2. In one embodiment, the DNA probes are capable of hybridizing to the entire genome of HIV-2. These reagents also include polypeptides encoded by some of these DNA sequences.

Abstract translation: 公开了用于诊断HIV-2（LAV-II）感染的方法和用于其的试剂盒。 这些试剂包括能够与HIV-2的至少一部分基因组杂交的cDNA探针。 在一个实施方案中，DNA探针能够与HIV-2的整个基因组杂交。 这些试剂还包括由这些DNA序列中的一些编码的多肽。

公开(公告)号：US06107019A

公开(公告)日：2000-08-22

申请号：US876078

申请日：1997-06-13

Applicant: Graham P. Allaway ,  Virginia M. Litwin ,  Paul J. Maddon ,  William C. Olson

Inventor： Graham P. Allaway ,  Virginia M. Litwin ,  Paul J. Maddon ,  William C. Olson

IPC: A61K38/00 ,  C07K14/16 ,  C07K14/52 ,  C07K14/715 ,  C07K14/73 ,  G01N33/566 ,  G01N33/569 ,  G01N33/68 ,  C12Q1/70

CPC classification number: C07K14/005 ,  C07K14/522 ,  C07K14/523 ,  C07K14/70514 ,  C07K14/7158 ,  G01N33/566 ,  G01N33/56988 ,  G01N33/6854 ,  A61K38/00 ,  C12N2740/16122 ,  G01N2333/162 ,  G01N2333/70514 ,  G01N2333/715 ,  G01N2500/00 ,  G01N2500/20

Abstract: This invention provides methods for inhibiting fusion of HIV-1 to CD4.sup.+ cells which comprise contacting CD4.sup.+ cells with a non-chemokine agent capable of binding to a chemokine receptor in an amount and under conditions such that fusion of HIV-1 to the CD4.sup.+ cells is inhibited. This invention also provides methods for inhibiting HIV-1 infection of CD4.sup.+ cells which comprise contacting CD4.sup.+ cells with a non-chemokine agent capable of binding to a chemokine receptor in an amount and under conditions such that fusion of HIV-1 to the CD4.sup.+ cells is inhibited, thereby inhibiting the HIV-1 infection. This invention provides non-chemokine agents capable of binding to the chemokine receptor and inhibiting fusion of HIV-1 to CD4.sup.+ cells. This invention also provides pharmaceutical compositions comprising an amount of the non-chemokine agent capable of binding to the chemokine receptor and inhibiting fusion of HIV-1 to CD4.sup.+ cells effective to prevent fusion of HIV-1 to CD4.sup.+ cells and a pharmaceutically acceptable carrier.

公开(公告)号：US06037165A

公开(公告)日：2000-03-14

申请号：US470487

申请日：1995-06-06

Applicant: Luc Montagnier ,  Solange Chamaret ,  Denise Guetard ,  Marc Alizon ,  Fran.cedilla.ois Clavel ,  Mireille Guyader ,  Pierre Sonigo ,  Fran.cedilla.oise Brun-Vezinet ,  Marianne Rey ,  Christine Rouzioux ,  Christine Katlama

Inventor： Luc Montagnier ,  Solange Chamaret ,  Denise Guetard ,  Marc Alizon ,  Fran.cedilla.ois Clavel ,  Mireille Guyader ,  Pierre Sonigo ,  Fran.cedilla.oise Brun-Vezinet ,  Marianne Rey ,  Christine Rouzioux ,  Christine Katlama

IPC: A61K38/00 ,  A61K39/00 ,  A61K39/21 ,  C07H21/02 ,  C07K7/06 ,  C07K14/16 ,  C12N7/00 ,  C12Q1/68 ,  C12Q1/70 ,  G01N33/53 ,  G01N33/569

CPC classification number: C07K7/06 ,  C07K14/005 ,  C12N7/00 ,  C12Q1/703 ,  G01N33/56988 ,  A61K38/00 ,  A61K39/00 ,  C12N2740/16021 ,  C12N2740/16122 ,  C12N2740/16222 ,  G01N2333/162 ,  G01N2469/20

Abstract: Methods for producing the newly discovered HIV-2 retrovirus and its antigens are provided. The antigens are obtained from various HIV-2 retroviruses. The antigen compositions comprise a lysate of an HIV-2 retrovirus, a protein of an HIV-2 retrovirus, or a glycoprotein of an HIV-2 retrovirus. Specifically, the antigen composition can comprise p12, p16, p26, gp32, gp42, and gp140.

Abstract translation: 提供了新发现的HIV-2逆转录病毒及其抗原的制备方法。 抗原是从各种HIV-2逆转录病毒获得的。 抗原组合物包含HIV-2逆转录病毒的裂解物，HIV-2逆转录病毒的蛋白质或HIV-2逆转录病毒的糖蛋白。 具体地，抗原组合物可以包含p12，p16，p26，gp32，gp42和gp140。

公开(公告)号：US5627043A

公开(公告)日：1997-05-06

申请号：US437820

申请日：1995-05-09

Applicant: Alex Franzusoff

Inventor： Alex Franzusoff

IPC: A61K36/064 ,  A61K38/00 ,  A61K39/39 ,  A61K47/48 ,  A61K48/00 ,  C07K14/16 ,  C12N1/19 ,  C12N9/00 ,  C12N9/60 ,  C12N9/64 ,  C12N15/00 ,  C12N15/113 ,  C12N15/81 ,  C12N15/82 ,  C12Q1/00 ,  C12Q1/02 ,  C12Q1/37

CPC classification number: C12Q1/37 ,  A61K36/064 ,  A61K39/39 ,  A61K47/48776 ,  C07K14/005 ,  C12N15/1137 ,  C12N15/81 ,  C12N15/8201 ,  C12N15/8279 ,  C12N9/60 ,  C12N9/6454 ,  C12Q1/025 ,  A61K38/00 ,  C07K2319/00 ,  C12N2740/16122 ,  C12Q2337/22 ,  G01N2333/162 ,  G01N2333/395 ,  Y10S435/81 ,  Y10S435/942 ,  Y10S435/975

Abstract: The present invention relates to novel yeast strains which produce a heterologous precursor protein having a dibasic amino acid processing site which can be processed into at least one cleavage protein by a dibasic amino acid processing endoprotease. Such novel yeast strains are useful for identifying compounds capable of inhibiting infectious agents, such as viruses, that depend upon dibasic amino acid processing endoprotease cleavage for effective propagation and/or infectivity.

Abstract translation: 本发明涉及产生具有二元氨基酸加工位点的异源前体蛋白质的新型酵母菌株，其可通过二元氨基酸加工内蛋白酶加工成至少一种切割蛋白质。 这样的新型酵母菌株可用于鉴定能够抑制感染因子（例如病毒）的化合物，其依赖于二元氨基酸处理内切蛋白酶裂解以有效传播和/或感染。